Translating Biomarker & Quality of Life Evaluation into Precision Medicine Approaches in HFpEF
Time: 1:45 pm
day: Day Two
Details:
- Describe risk factors and disease endotypes in evaluation for HFpEF clinical trials
- Define the state of proteomic/genomic, digital and cardiac imaging in precision medicine evaluation of HFpEF symptoms and disease progression
- Discuss the evolving landscape of HFpEF clinical trials and opportunities
for precision medicine
